A gene ther­a­py pi­o­neer moves from Bio­gen to Re­genxbio, stay­ing fo­cused on gene ther­a­py 2.0

Olivi­er Danos’ ar­rival as head of Bio­gen’s gene ther­a­py group two-and-a-half years ago sig­naled an im­por­tant shift in the big biotech’s R&D fo­cus. In swift or­der Bio­gen ex­e­cut­ed a part­ner­ship with the San Raf­faele-Telethon In­sti­tute for Gene Ther­a­py, inked a $1 bil­lion-plus deal with AGTC and fol­lowed up with a $2 bil­lion pact to work with James Wil­son and Jean Ben­nett at the Uni­ver­si­ty of Penn­syl­va­nia.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.